跳至主要内容
临床试验/NCT07216495
NCT07216495招募中不适用

Pilot Study of an Aerobic Exercise Intervention During Immune Checkpoint Inhibitor Therapy in Early-stage Triple Negative Breast Cancer

M.D. Anderson Cancer Center1 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2026年2月23日最近更新:
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
33
试验地点
1
主要终点
Adherence

研究概览

简要总结

To learn if participating in a supervised exercise program can help participants with early-stage TNBC who are receiving ICI therapy before undergoing breast surgery.

详细描述

Primary Objective To evaluate the feasibility of a supervised cardiorespiratory exercise program in patients with clinical stage 2-3 Triple Negative Breast Cancer (TNBC) undergoing neoadjuvant chemotherapy with immune checkpoint inhibitor therapy.

Secondary Objectives To explore the relationship between cardiorespiratory exercise and circulating immune (CD8+ T) cells in the peripheral blood.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • female and male participants 18 years or older and willing to provide Informed Consent
  • clinical stage 2 or 3 TNBC (estrogen receptor and progesterone receptor ≤ 10% by immunohistochemistry (IHC) and human epidermal growth factor-2 (HER2) negative (IHC 0, IHC1+, or IHC 2+ with negative fluorescence in situ hybridization))
  • Physically able to walk independently without assistive device and able to march in place for 30 seconds without assistive device
  • Eastern Co-Operative Oncology Group (ECOG) Performance Status 0-1
  • Planned receipt of neoadjuvant chemoICI therapy (carboplatin/taxane in combination with pembrolizumab; taxane options are weekly paclitaxel or every 3 week docetaxel)
  • clearance to participate in the study by the patient's medical oncologist
  • normal bone marrow function
  • able to read/complete study forms/assessments and understand instructions in English

排除标准

  • a) Any physical condition which hinders the ability to safely participate in exercise including: uncontrolled or symptomatic cardiac/respiratory disease (e.g. uncontrolled angina, unusual shortness of breath, congestive heart failure, symptomatic peripheral vascular disease), stroke/myocardial infarction in the past year, fragility fracture, recent or planned orthopedic surgery, or any comorbid condition precluding exercise per the treating physician b) receipt of medications known to influence immune function including corticosteroids (>10 mg prednisone equivalent), other immune-suppressive medication, or beta blockers47 c) Any infection or vaccination within the last 4 weeks d) e) Known HIV-positive participants on combination antiretroviral therapy f) concurrent participation in a therapeutic clinical trial or other exercise program g) pregnant h) medically advised to not exercise i) Unable to walk on a motor-driven treadmill for ~30 minutes at study enrollment j) Adults unable to consent k) No external catheters/drains (e.g., nephrostomy tube, foley catheter). A colostomy or Ileostomy is acceptable.
  • l) Prior or concurrent non-breast malignancy. Those with prior cancers treated with curative intent are eligible. Participants with known (or history) of hepatitis B positive, or hepatitis C positive infection

研究组 & 干预措施

Acute cardiorespiratory exercise program

Experimental

consisting of 4 in-clinic exercise sessions

干预措施: Exercise (Other)

结局指标

主要结局

Adherence

时间窗: Approximately 8 weeks

Feasibility will be measured by adherence to both exercise frequency and time (duration/intensity) at the supervised sessions.

次要结局

  • Circulating immune (CD8+ T) cells in the peripheral blood(Approximately 8 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验